Pay in 4 interest-free payments of $7.44 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Risk factors that may influence the decision to pause treatment include: Being in the dose-escalation phase of GLP-1 therapy Experiencing active gastrointestinal symptoms (nausea, vomiting, bloating) Having known gastroparesis or other conditions affecting gastric emptying Taking concurrent medications that further delay gastric emptying (e.g., opioids) Undergoing procedures with higher aspiration risk (e.g., emergency surgery, airway surgery) If your anaesthetist or surgical team advises temporary cessation based on your individual risk assessment, the timing will depend on the specific medication: Daily injections (such as liraglutide): Typically paused 24 hours before surgery Weekly injections (such as semaglutide, dulaglutide): Often paused with the last dose given at least 7 days before surgery Oral semaglutide (Rybelsus): Usually paused 24 hours before surgery [4] However, these timings may vary according to local NHS Trust protocols and individual clinical assessment
Consider advanced glutathione formulations if you want more direct cellular support or need support for antioxidant replenishment
Brown MK, Strus E, Naidoo N (2017) Reduced sleep during social isolation leads to cellular stress and induction of the unfolded protein response
Most CJC 1295 and Ipamorelin protocols use a small subcutaneous injection given at night before sleep
Chan JCN, Lim LL, Wareham NJ, et al
